Tirzepatide
US$ 29.56
semaglutide news oct 26 2025 Drug compounders sue FDA over declaration ending Wegovy shortage Trump announces $50/month GLP-1 weight
Description
launch expected in early 2026 This approval expands treatment options and marks a major milestone for GLP-1 therapies
Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions.
Explore the scientific mechanism of Semaglutide as a GLP-1 agonist and how it supports weight loss
Feed Your Gut Cells & Support Natural GLP-1 Pathways*
Learn more about HIMS stock here.
Research-grade Retatrutide (GLP-3 / LY3437943), 1030 mg per vial
